Akebia Therapeutics Stock News

Biopharma Akebia Therapeutics (AKBA) skyrocketed 38% in Tuesday’s trading after reporting positive topline data from the global Phase 3 clinical trials of vadadustat.This is the company’s investig

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

AKBA earnings call for the period ending March 31, 2020.

Shares of Akebia Therapeutics (NASDAQ: AKBA) were skyrocketing 37.3% higher as of 11:25 a.m. EDT on Tuesday. The huge jump came after the biotech announced positive results from a late-stage clinical

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results.Quarterly Results Earnings per share fell 6.82% year over year to ($0.47), which beat the estimate of ($0.6

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced positive top-line results from INNO2VATE, its global Phase 3 cardiovascular outcomes program evaluating the efficacy and safety of vadadustat,

Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. The

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 5.) Arcturus Therapeutics Ltd (...

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genocea Biosciences (GNCA), Chemed (CHE) and BioMarin